News & Updates

Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.

Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.

The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.

Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).

The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.